Dr Reddy’s Laboratories on Friday said that the US Food and Drug Administration (USFDA) has sent it a warning letter for inadequate quality control procedures at its three drug manufacturing units. “We will respond with a... plan to address these observations within... 15 days,” the drugmaker’s CEO said. Following the acknowledgment, the company’s share price fell 14.5% during intra-day trade.
